Commentary

Video

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

Author(s):

John M. Burke, MD, Rocky Mountain Cancer Centers
Conference|ASH Annual Meeting and Exposition

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

John M. Burke, MD, hematologist, medical oncologist, Rocky Mountain Cancer Centers, Sarah Cannon Cancer Institute, discusses results from a United States community-based healthcare practitioner survey, highlighting best practices to overcoming challenges in initiating venetoclax (Venclexta) for patients with chronic lymphocytic leukemia. These findings were presented by Burke at the 2024 ASH Annual Meeting.

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Related Content
Supriya Gupta, MD
January 9th 2025

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 9th 2025

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Nirav N. Shah, MD
January 7th 2025

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

Cervical Cancer| lertsakwiman – stock.adobe.com
January 6th 2025

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer